KZR

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

Wall Street analysts forecast KZR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kezar Life Sciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Kezar Life Sciences Inc. EPS for the last quarter amounts to -1.53 USD, decreased -94.50 % YoY.

Kezar Life Sciences Inc (KZR) has 55 emplpoyees as of December 15 2025.

Today KZR has the market capitalization of 45.70M USD.